Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q3 2017 · 10-Q
Revenue$6.08M$6.08M+54.5% vs Q3 2016 Net Income$2.14M$2.14MN/M vs Q3 2016 EPS Diluted$0.04$0.04N/M vs Q3 2016 Gross Profit$2,915,369+42.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$475,321N/M Free Cash Flowderived-$1,052,458N/M Margins · derivedGross margin47.9%−4.0 pt vs Q3 2016
Operating margin-52.2%−28.2 pt vs Q3 2016
Net margin35.1%+59.4 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 9, 2017 · 40 d after period end